P1736-05

P1736-05 is an orally active, small molecule insulin-sensitizing compound developed by Piramal Life Sciences for the treatment of type 2 diabetes mellitus. It is a non-thiazolidinedione (non-TZD) and non-PPARγ compound, distinguishing it from traditional insulin sensitizers that activate the peroxisome proliferator-activated receptor gamma. Its mechanism of action involves inducing the translocation of GLUT-4 (glucose transporter type 4) to the cell membrane in insulin-resistant adipocytes, thereby enhancing peripheral insulin sensitivity and glucose uptake. Preclinical studies showed that P1736-05 lowered plasma glucose and triglyceride levels without the adverse effects on body weight or liver function typically associated with PPARγ agonists. The compound underwent a Phase II, 12-week randomized, double-blind, placebo-controlled proof-of-concept trial to evaluate its safety, tolerability, pharmacokinetics, and glycemic effects in adults with type 2 diabetes.